Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: The SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE v Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects with de Novo Native Coronary Artery Lesions) and SPIRIT IV

JACC: Cardiovascular Interventions

Volumn 3, Issue 12, 2010, Pages 1229-1239

  Kereiakes, Dean J ^a   Sudhir, Krishnankutty ^c   Hermiller, James B ^d   Gordon, Paul C ^e   Ferguson, Joanne ^c   Yaqub, Manejeh ^c   Sood, Poornima ^c   Su, Xiaolu ^c   Yakubov, Steven ^b   Lansky, Alexandra J ^f   Stone, Gregg W ^f  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b RIVERSIDE METHODIST HOSPITAL   (United States)

^c ABBOTT VASCULAR   (United States)

^d Care Group   (United States)

^e MIRIAM HOSPITAL   (United States)

^f NewYork Presbyterian Hospital   (United States)

Author keywords

drug eluting stent(s); everolimus; major adverse cardiac events; stent

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; EVEROLIMUS; PACLITAXEL;

ARTERY LESION; ARTICLE; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE THERAPY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION;

ANGIOPLASTY, BALLOON, CORONARY; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TIME FACTORS; UNITED STATES;

EID: 78651424782     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.09.014     Document Type: Article

References (26)

1. A.J. Kirtane, A. Gupta, and S. Iyengar Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies Circulation 119 2009 3198 3206
2. P.W. Serruys, M.J. Kutryk, and A.T. Ong Coronary-artery stents N Engl J Med 354 2006 483 495
3. J.M. Galla, D.J. Kumbhani, M.C. Becker, and S.G. Ellis Off-label use of drug-eluting stents is associated with a reduction in all-cause mortality compared with bare-metal stents: results from a combined analysis (abstr) Circulation 118 2008 S1040 S1041
4. A.T. Ong, P.W. Serruys, and J. Aoki The unrestricted use of paclitaxel-versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry J Am Coll Cardiol 45 2005 1135 1141
5. F. Airoldi, A. Colombo, and N. Morici Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment Circulation 116 2007 745 754
6. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678
7. E.L. Eisenstein, K.J. Anstrom, and D.F. Kong Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
8. Applegate R, Hermiller JB Jr., Sanz M, et al. Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two vessels treatment: 2-year results from the SPIRIT III randomized trial. Paper presented at: Transcatheter Therapeutics Conference; September 22, 2009; San Francisco, CA.
9. P.W. Serruys, M.-C. Morice, A.P. Kappetein SYNTAX Investigators Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease N Engl J Med 360 2009 961 972
10. M. Valgimigli, P.W. Serruys, K. Tsuchida ARTS II Investigators Cyphering the complexity of coronary artery disease using the SYNTAX score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention Am J Cardiol 99 2007 1072 1081
11. P.W. Serruys, P. Ruygrok, and J. Neuzner A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial EuroIntervention 2 2006 286 294
12. G.W. Stone, M. Midei, W. Newman SPIRIT III Investigators Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913
13. Stone GW. The XIENCE V everolimus-eluting stent: comprehensive update of the clinical trial programfeaturing the first presentation of the SPIRIT III 3-year results. Paper presented at: Transcatheter Therapeutics Conference; September 21, 2009; San Francisco, CA.
14. G.W. Stone, M. Midei, W. Newman SPIRIT III Investigators Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with De Novo Native Coronary Artery Lesions (SPIRIT) III Trial Circulation 119 2009 680 686
15. G.W. Stone, A. Rizvi, W. Newman SPIRIT IV Investigators Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
16. E. Kedhi, K.S. Joesoef, and E. McFadden Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial Lancet 375 2010 201 209
17. E. Nikolsky, A.J. Lansky, and K. Sudhir SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease Am Heart J 158 2009 520 to 6:e2
18. D.E. Cutlip, S. Windecker, R. Mehran Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
19. S.J. Brener, B.W. Lytle, I.P. Casserly, J.P. Schneider, E.J. Topol, and M.S. Lauer Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features Circulation 109 2004 2290 2295
20. R. Mehran, G.D. Dangas, and Y. Kobayashi Short- and long-term results after multivessel stenting in diabetic patients J Am Coll Cardiol 43 2004 1348 1354
21. K.D. Dawkins, E. Grube, G. Guagliumi TAXUS IV Investigators Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice Circulation 112 2005 3306 3313
22. M.W. Krucoff, D.J. Kereiakes, J.L. Petersen COSTAR II Investigators Group A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent with Antiproliferative for Restenosis) II Study J Am Coll Cardiol 51 2008 1543 1552
23. D. Orlic, E. Bonizzoni, and G. Stankovic Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results J Am Coll Cardiol 43 2004 1154 1160
24. J.M. de La Torre-Hernndez, F. Alfonso, F. Hernndez ESTROFA Study Group Drug-eluting stent thrombosis: results from the Multicenter Spanish Registry ESTROFA (Estudio ESpaol sobre TROmbosis de stents FArmacoactivos) J Am Coll Cardiol 51 2008 986 990
25. R. Moreno, C. Fernndez, and R. Hernndez Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies J Am Coll Cardiol 45 2005 954 959
26. S. Shirai, T. Kimura, M. Nobuyoshi j-Cypher Registry Impact of multiple and long sirolimus-eluting stent implantation on 3-year clinical outcomes in the j-Cypher Registry J Am Coll Cardiol Intv 3 2010 180 188